Telomir Pharmaceuticals, Inc. Common Stock – NASDAQ:TELO

Add to watchlist

$1.45

-3.42

-70.23%

Market closed

Open in 2 days

+17.92%

month

+17.92%

quarter

Market Cap	140.13M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO): Profit margin
2023	0	-13.07M

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO): Debt to assets
2023	4773768	1.33M	27.98%

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO): Cash Flow
2022	-468.66K	0	470.08K
2023	-3.85M	0	3.85M

Telomir Pharmaceuticals, Inc. Common Stock alternative data

Telomir Pharmaceuticals, Inc. Common Stock
Employees

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO): Employee count
Mar 2024	2
Apr 2024	2
May 2024	1
Jun 2024	1
Jul 2024	1
Dec 2024	1

Telomir Pharmaceuticals, Inc. Common Stock
Latest News

Monday, 23 December 2024
07:30	Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease	accesswire.com
Thursday, 12 December 2024
08:30	Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price	accesswire.com
Tuesday, 3 December 2024
13:40	Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?	benzinga.com
Thursday, 21 November 2024
07:00	Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1	accesswire.com
Thursday, 26 September 2024
16:00	Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday	accesswire.com
Tuesday, 10 September 2024
08:45	Telo Genomics Assessing MRD Status in TELO-DMRD Study	newsfilecorp.com
Wednesday, 4 September 2024
07:30	Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications	accesswire.com
Tuesday, 20 August 2024
07:30	Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs	accesswire.com
Monday, 12 August 2024
08:30	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman	globenewswire.com
Tuesday, 2 July 2024
08:30	Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes	globenewswire.com
Monday, 17 June 2024
16:10	Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel	globenewswire.com
Thursday, 30 May 2024
08:30	Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1	globenewswire.com
Tuesday, 16 April 2024
08:30	Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.	globenewswire.com
Tuesday, 2 April 2024
08:30	Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 10 Feb 2024

U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week

Frequently Asked Questions (FAQ)

What's the price of Telomir Pharmaceuticals, Inc. Common Stock stock today?

One share of Telomir Pharmaceuticals, Inc. Common Stock stock can currently be purchased for approximately $1.45.
When is Telomir Pharmaceuticals, Inc. Common Stock's next earnings date?

Unfortunately, Telomir Pharmaceuticals, Inc. Common Stock's (TELO) next earnings date is currently unknown.
Does Telomir Pharmaceuticals, Inc. Common Stock pay dividends?

No, Telomir Pharmaceuticals, Inc. Common Stock does not pay dividends.
How much money does Telomir Pharmaceuticals, Inc. Common Stock make?

Telomir Pharmaceuticals, Inc. Common Stock has a market capitalization of 140.13M.
What is Telomir Pharmaceuticals, Inc. Common Stock's stock symbol?

Telomir Pharmaceuticals, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "TELO".
What is Telomir Pharmaceuticals, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Telomir Pharmaceuticals, Inc. Common Stock?

Shares of Telomir Pharmaceuticals, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Telomir Pharmaceuticals, Inc. Common Stock have?

As Dec 2024, Telomir Pharmaceuticals, Inc. Common Stock employs 1 workers.
When Telomir Pharmaceuticals, Inc. Common Stock went public?

Telomir Pharmaceuticals, Inc. Common Stock is publicly traded company for more then 6 years since IPO on 9 Apr 2019.
What is Telomir Pharmaceuticals, Inc. Common Stock's official website?

The official website for Telomir Pharmaceuticals, Inc. Common Stock is telomirpharma.com.
How can i contact Telomir Pharmaceuticals, Inc. Common Stock?

Telomir Pharmaceuticals, Inc. Common Stock can be reached via phone at +7 372890835.

Telomir Pharmaceuticals, Inc. Common Stock

telomirpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

+7 372890835

855 N Wolfe Street
Baltimore, 21205

CIK: 0001971532
ISIN: US87975F1049
: